Johns Hopkins POC-IT: Point of Care Information Technology [Home]
HIV Guide
 Zambia HIV National Guidelines
 


Introduction  

HIV Counseling and Testing  

Sexually Transmitted Infections (STIs)  

General Principles of Antiretroviral Therapy for Chronic HIV Infection in Adults and Adolescents  

When to Start ARV Therapy for Chronic HIV Infection in Adults and Adolescents  

Initial Regimen for ARV Therapy  

Adherence  

Baseline evaluation and Monitoring  

Calculations: Ideal Body Weight, Body Mass Index and Creatinine Clearance  

ARV Therapy for Individuals with Tuberculosis Co-Infection  

Adverse Effects and Toxicity  

Immune Reconstitution Inflammatory Syndrome (IRIS)  

Changing or Stopping ART  

Treatment Failure  

Stopping ARV Therapy  

Post Exposure Prophylaxis  

Cotrimoxazole Prophylaxis  

WHO Staging in Adults and Adolescents  

Nutrition Care and Support  

Palliative Care in HIV and AIDS  

 Guide Editors
 Editor In Chief
    Joel E. Gallant, MD, MPH

Pharmacology Editor
    Paul Pham, PharmD, BCPS

Zambia Guideline Team
   Peter Mwaba MMed PhD FRCP
   Alywn Mwinga MMed
   Isaac Zulu MMed MPH
   Velepie Mtonga MMed
   Albert Mwango MBChB
   Jabbin Mulwanda MMed FCS
 

 

 

Diagnosis>Complications of Therapy>
HIV Guide Home PageEmail this module to a friend

Immune reconstitution inflammatory syndrome (IRIS)

Kathleen R. Page, M.D. and Adriana Andrade, M.D., M.P.H.
02-13-2008

Zambia Specific Information

  • In Zambia no specific data on incidence/prevalence but IRIS thought to occur in ~10% of all pts on ART, up to 25% when ART started at CD4 <50.
  • IRIS in Zambia most common with TB, cryptococcosis, and M. avium complex.
  • 2 types of IRIS: 1) “paradoxical” IRIS - HIV+ pts with OI Dx and improving on OI treatment (or have completed treatment) but develop paradoxical worsening or recurrence of OI manifestations (Sx, signs, or radiological features) shortly after starting HAART; and 2) “unmasking” IRIS - HIV+ pts with unrecognized OI begin HAART and subsequently develop clinical manifestations of OI which may have prominent inflammatory component. Both types most common with TB (McIlleron H, Meintjes G, Burman WJ, et al. reference).
  • Maintain high index of suspicion for IRIS in first weeks to months after starting HAART.
  • Dx often made clinically, but Bx or Cx of lymph nodes, masses, or abscess fluid useful to confirm Dx.
  • DDx and general management principles are as listed below.
  • Specific Management per Zambia National Guidelines on Management and Care for HIV/AIDS 2007: 
  • --If HIV+ pt is severely ill with TB , other stage 3/4 disease or CD4 < 200, hold ART until TB medications are tolerated (usually 2-3 wks); if HIV+ pt with TB and CD4 200-350 or clinical deterioration, start ART after intensive phase of TB treatment; if HIV+ pt with TB has CD4 > 350 or clinically stable, consider ART after completion of TB treatment.
  • --General Management of IRIS: ART should be continued; however, if continuation impossible, temporarily interrupt ART and restart same regimen after OI or inflammatory condition treated.
  • --Corticosteroid treatment in moderate to severe cases: prednisolone or prednisone 0.5 mg/kg/day for 5-10 days. (Author note: longer courses may sometimes be necessary depending on clinical response to taper or discontinuation)

REFERENCES

Zambia Information Author: David Riedel, M.D.

CLINICAL

  • Paradoxical deterioration in clinical status after ART initiation despite improved immune function due to inflammatory response against infectious antigen, which may or may not have been Dx'd at initiation of ART.
  • Typically occurs in pts with low initial CD4 (usually <50) and rapid decline in viral load; onset usually within 6 wks of ART initiation, but sometimes several mos later.
  • Inciting pathogens: M. avium complex, (30% of cases), and other Mycobacteria, CMV, Cryptococcus, PCP, Leishmania, HSV, VZV, hepatitis B and C, JC virus, HHV8 (Kaposi's and Castleman's), JC virus (PML), and others.
  • Common Sx (varies according to causative pathogen): fever, localized lymphadenophathy/lymphadenitis, abscesses, pneumonia, vitritis, CNS disease, hepatitis, and dermatologic manifestations.
  • Presentations of OIs may be atypical (eg, MAC: localized granulomatous lymphadenopathy without mycobacteremia; CMV: vitritis; PML: enhancing CNS lesions; Cryptococcus: marked CSF leukocytosis).
  • Autoimmune diseases (e.g.sarcoidosis, Grave's disease) may be exacerbated
  • Despite high risk (>25%) of paradoxical worsening in pts with active TB after initiation of ART, overall mortality improved in coinfected pts with CD4<100 treated with ART.

DIAGNOSIS

  • Compatible presentation after initiation of ART (usually within 6 wks, with rising CD4 and decrease in VL).
  • DDx includes new OI, malignancy (e.g. lymphoma), treatment failure for OI, and drug toxicity (especially with hepatitis).

TREATMENT

General principles

  • Treat underlying active infection (refer to specific pathogen module)
  • Continue ART, unless inflammatory response is life threatening
  • Anti-inflammatory therapy (NSAIDS and/or corticosteroids)
  • Response to corticosteroids typically rapid. Slow taper may be required
  • Initiation of ART during the treatment of an active OIs is controversial. Timing of ART depends on severity of OI and degree of immunosuppression. Studies in progress.
Pathogen-specific considerations

  • MAC (lymphadenitis): NSAIDS, if Sx persist, 20-40 mg/d prednisone with slow taper, titrating to recurrence of symptoms. Abscesses may be surgically drained.
  • : prednisone 20-40 mg/d for 2 wks with slow taper. In pts with active TB not on antiretrovirals, consider treating TB for >2 mos before starting HAART unless CD4<100. Delayed ART in TB-HIV co-infected pts with CD4 <100 associated with high risk of morbidity and mortality in African studies.
  • CMV vitritis: systemic or periocular steroids, 50% respond
  • Hepatitis: consider using TDF + either 3TC or FTC in pts infected with HBV coinfection. Consider discontinuing ART if serious drug toxicity suspected. Risk of reversible drug-related hepatotoxicity highest with full-dose RTV (rarely used), but tends to occur >6 wks into therapy. NVP hepatotoxicity occurs early (within 6 wks), may be associated with rash and can be fatal, but rarely observed with pre-treatment CD4 <250.
  • Cryptococcal meningitis: usually Cx negative, but higher CSF opening pressure. Steroids, serial LPs to manage elevated CSF pressure. Interruption of ART may be necessary in severe or unresponsive cases. 

REFERENCES

REFERENCED WITHIN THIS GUIDE


 
Diagnosis
 


Complications of Therapy


Malignancies


Miscellaneous


Opportunistic Infections


Organ System

Drugs
 


Antimicrobial Agents


Antiretrovirals


Miscellaneous

Guidelines
 


Zambia HIV National Guidelines

Management
 


Antiretroviral Therapy


Laboratory Testing


Miscellaneous

Pathogens
 


Bacteria


Fungi


Parasites


Viruses

View All Modules
 
Index
 
 
Contacts    Help    Copyright    Acknowledgments    Abbreviations